Recarbrio (Imipenem/Cilastatin/Relebactam) Patent Expiration, LOE Window & CMS Spending

Recarbrio (Imipenem/Cilastatin/Relebactam) by Merck & Co.: FDA Orange Book core substance LOE 2033-03-21, 0 AB generics, $1.7M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMerck & Co.
FDA Application & PathwayN212819 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2033-03-21
Last Listed Patent or Exclusivity Date2033-03-21
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.7M
2024 Medicare Part D Spend$1.2M
2024 Medicaid Spend$517K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Merck & Co. across sibling Meru public-data platforms.